Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma

INTRODUCTION: Treatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor. METHODS: Patients with mRCC treated with everolimus (EV) or sorafenib (SO) after two previous lines of targeted therapies...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Can Urol Assoc J
Autores principales: Iacovelli, Roberto, Santini, Daniele, Rizzo, Mimma, Felici, Alessandra, Santoni, Matteo, Verzoni, Elena, Masini, Cristina, Massari, Francesco, Calvani, Nicola, Mosca, Alessandra, Procopio, Giuseppe
Formato: Artigo
Lenguaje:Inglês
Publicado: Canadian Medical Association 2015
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4537338/
https://ncbi.nlm.nih.gov/pubmed/26316911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2377
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares